白蛋白结合型紫杉醇治疗晚期恶性肿瘤的临床观察

Clinical effects of Albumin-bound Paclitaxel in the treatment of advanced malignant tumors

目的:观察白蛋白结合型紫杉醇治疗晚期恶性肿瘤的疗效及毒副作用。方法:对采用含白蛋白结合型紫杉醇方案化疗的晚期恶性肿瘤患者32例进行回顾性分析,每例患者接受1-6个周期化疗,中位化疗4个周期。每2个周期后按照RECIST实体瘤近期客观疗效评定标准进行疗效评价。观察疗效和不良反应。结果:30例可评价疗效,完全缓解(CR)1例,部分缓解(PR)13例,稳定(SD)7例,疾病进展(PD)9例。客观有效率(RR=CR+PR)46.6%,临床获益率(CR+PR+SD)为70.0%。不良反应主要为骨髓抑制、消化道反应、感觉神经毒性。结论:白蛋白结合型紫杉醇治疗晚期恶性肿瘤,疗效较好,毒副反应小,值得临床上进一步推广应用。

Objective：To observe the efficacy and safety of Albumin - bound Paclitaxel in treatment of patients with advanced malignant tumors. Methods： Thirty - two patients with advanced malignant tumors treated with Albumin - bound Paclitaxel and other chemotherapy drugs were analyzed. All patients received 1 - 6 cycles of chemotherapy. The patients were assessed on the basis of Response Evaluation Criteria in Solid Tumors（RECIST） after 2 cycles. Re- suits：Thirty patients were assessable for the efficacy. Of them, 1 had complete response, 13 partial response,7 stable disease and 9 progression disease. The over - all response rate was 46.6% （14/30） ,clinical tumor control rate was 70.0% （21/30）. The main toxic reactions were leukopenia, nausea and vomiting, neutropenia. Conclusion： Albumin - bound Paclitaxel is effective and well tolerable in treatment for advanced malignant tumors.